The Association of the British Pharmaceutical Industry, in conjunction with the Office of Health Economics, invites you to register for a webinar on Monday 18th July: New EQ-5D-5L value sets for England and the UK and implications for HTA.
The EQ-5D is one of the most widely used generic measures of health related quality of life (HRQL), and is the instrument recommended by the National Institute for Health and Care Excellence (NICE) for use in estimating Quality Adjusted Life Years (QALYs) in cost effectiveness analysis. It is accompanied by a range of country-specific ‘value sets’, reporting the HRQL weights for each of the health states described by its 5 dimensions and 3 levels (243 states). The UK value set for the EQ-5D has been used extensively in NICE health technology assessments (HTA), and was also influential in other countries – but is now nearly two decades old.
In 2011, a new version of the EQ-5D – the EQ-5D-5L – was published, expanding the number of response options from 3 levels (no, some, extreme problems) to 5 (no, mild, moderate, severe, extreme). This increases the number of health states from 243 to 3,125, with the aim of increasing the sensitivity and responsiveness of the instrument.
The EQ-5D-5L is already being used in clinical trials and other studies providing evidence for HTA submissions. A value set for the EQ-5D-5L has recently been reported for England (Devlin et al. 2016; Feng et al. 2016) and the UK. This has some important differences from the previous value set – with implications for its use in HTA.
The aims of this webinar are to:
- Explain why a new value set was required
- Describe the methods used to elicit values for the EQ-5D-5L in England and the UK (and other countries undertaking similar studies)
- Summarise the new modelling methods used to produce the EQ-5D-5L value set for England and the UK
- Present the new value set, and illustrate how it is used to calculate the values for EQ-5D-5L health states.
- Highlight key differences between the new EQ-5D-5L value set and the previous EQ-5D value set (and the ‘crosswalk’ value set between the 5L and 3L versions).
- Discuss the implications of these differences for the analysis of HRQoL data for HTA purposes
- Provide an opportunity for the research team to answer any questions which you may have about the study and its implications.
Given the interest we expect in this seminar, we invite you to submit questions in advance, and these will be prioritised for responses. Once these have been addressed, and if time remains, there will be an opportunity to ‘open the floor’ for additional questions.
To register for the seminar and to submit questions, please click here.
